regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant FDA approves Regeneron drug for

Irish Journal of Medical Science

The medication activates GLP-1 (glucagon-like peptide-1) receptors to promote insulin release, slow gastric emptying, and suppress appetite

The researchers calculated what they termed the fat loss index, which represents the ratio of fat mass lost to total body mass lost

This perspective promotes the development of integrative medicine models, emphasizing the intrinsic connection between somatic and psychiatric symptoms and suggesting the need for multidisciplinary collaboration between gastroenterology and psychiatry

Hypothyroid patients may have an increased risk for digitalis toxicity

Our approach ensures you have the right tools and support to reach your weight loss goals in a safe, effective, and sustainable way